FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average I	burden
hours par response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	5)															
1. Name and Address of Reporting Person *- Goodwin Bradford S			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner							
C/O RIG	(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/19/2021								Officer (give	e title below)	Oti	er (specify bel	ow)
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person							
(Cit		(State)	(Zip)	Tabla I. Nan Darivativa Securities Acqu					s Acqui	quired, Disposed of, or Beneficially Owned							
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	any	emed on Date, if	3. Transaction Code (Instr. 8)		1 4. (A	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		uired of (D)	5. Amount of Owned Follow Transaction(s)		Securities Beneficially wing Reported		6. Ownership Form:	Beneficial	
				(Month	/Day/Year	Coo	de V	V A	mount	(A) or (D)	Price	or Ind (I)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)		
Common Stock 05		05/19/2021			A		25 (1	5,000	A	\$ 0	35,000				D		
	Report on a s	separate line for each	n class of securities b	beneficia	lly owned	irectly	Per in t	sons	orm are	not re	equired	d to re	espond	unless the	tion contai	ned SEC	1474 (9-02)
	Report on a s	separate line for eacl	Table II -	Derivati	ive Securit	es Acq	Per in t dis juired, I	rsons this fo	orm are	not rently v	equired alid O ficially	d to re	espond ontrol n	unless the		ned SEC	1474 (9-02)
Reminder:	·		Table II -	Derivati	ive Securit	es Acq	Per in t dis uired, I	rsons his for plays Dispos	orm are is a curre sed of, or evertible	not re ntly v Benef securi	equired valid O ficially ities)	d to re	espond ontrol r	unless the	e form		, ,
	·	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., pu 4. Transac Code	ive Securit ts, calls, w 5. Nu tion of De Secur	nber ivative ties red (A)	Per in t dis uired, I s, option 6. Date Expira (Montl	rsons his for plays Disposes, constant Exertion E	orm are of a curre sed of, or avertible are contact.	Benefacturi	equired valid O ficially ities)	Owner and Alerlyin ties	espond control r ed Amount	unless the number.	9. Number Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form o Derivat Security Direct (or Indir (s) (I)	11. Natur of Indire f Beneficia Ownersh (Instr. 4)
Reminder: 1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., pu 4. Transac Code	sve Securit ts, calls, w 5. Nu tion of De Secur Acqu or Dis of (D (Instr	nber ivative ties red (A)	Per in t dispuired, I dispuired	Price Exertion Day	orm are of a curre sed of, or avertible are contact.	Benefaceuri	ficially (ties) 7. Title of Und	Owner and Alerlyin ties 3 and	espond control r ed Amount	8. Price of Derivative Security	9. Number Derivative Securities Beneficially Owned Following Reported	of 10. Owners Form o Derivat Security Direct (or Indir	11. Natur of Indire f Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Goodwin Bradford S C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/Dolly Vance (Attorney-in-Fact)	05/21/2021
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors.
- (2) The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.